Federal Register Notice: FDA has determined the regulatory review period for Roche Palo Alto, L.L.C.’s Ranexa, is 6,770 days for extending a patent which claims that human drug product. The agency recently approved for marketing Ranexa (ranolazine) for treating chronic angina. To view this notice, click here.
